Related Experiment Video
Updated: Jan 11, 2026
An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
Published on: January 26, 2019
Nirsevimab for preventing respiratory syncytial virus lower respiratory tract infections in infants: a systematic
Samira Soudani1, Lorenzo Bertizzolo2, Mehdi Ghemmouri1
1Sanofi, Global Health Economics and Value Assessment, Lyon, France.
Background:
Respiratory syncytial virus (RSV) causes lower respiratory tract infections (LRTIs) in infants, leading to substantial morbidity and mortality. Nirsevimab, a long-lasting monoclonal antibody, has been demonstrated to reduce RSV-related outcomes in randomized controlled trials (RCTs) and real-world settings. The object was to review the existing real-world evidence (RWE) on the effectiveness of nirsevimab in preventing RSV-LRTIs.
Methods:
Searches of six databases in addition to trial registries, HTA/regulatory agency webpages and conference abstracts were conducted in November 2024. Observational studies evaluating nirsevimab prophylaxis in infants during their first RSV season or high-risk infants in their second season were included. For outcomes evaluated by more than one study, feasibility assessment was conducted and, where appropriate, studies were combined in meta-analyses.
Results:
Sixteen studies reporting effectiveness outcomes were included. The studies were conducted across four countries (Spain, Italy, US and France), and included 141,550 infants. Nirsevimab showed significant effectiveness for preventing RSV-LRTI hospitalization (reduction in risk from hazard ratios and odds ratios of 84.5%; 95% CI: 73.6%-90.9%; I 2: 0 and 73.7%; 95% CI: 42.3%-88.0%; I 2: 0%, respectively), intensive care unit (ICU) admission (85.9%; 95% CI: 13.2%-97.7%) and ventilatory support (87.1%; 95% CI: 70.2%-94.4%). Nirsevimab was also effective in preventing RSV-LRTI visits in primary care (75.8%; 95% CI: 40.4%-92.7%) and emergency departments (87.9%; 70.3%-95.1%).
Conclusions:
Real-world evidence confirms the effectiveness of nirsevimab against RSV-LRTIs and underlines the public health impact of the intervention in preventing RSV-related health outcomes. There is no clear evidence that effectiveness differs for infants born in season (at birth immunization) compared with out of season groups, or that effectiveness varies in preterm infants compared to healthy term infants.
Systematic Review Registration:
https://www.crd.york.ac.uk/PROSPERO/view/CRD42024591323.
More Related Videos
Related Concept Videos
01:17Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:31Common Respiratory Disorders
Upper respiratory disorders impact the airways above the vocal cords, encompassing areas like the nose, sinuses, and throat. Various conditions fall under this category, including the common cold and allergic rhinitis. These disorders can stem from several causes,...
01:16Drugs Used in Upper Respiratory Disorders: Overview
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
01:15Upper Respiratory Drugs: First and Second-Generation Antihistamines
Histamine binds to specific receptor sites, known as H1 receptors, on tissue cells, triggering inflammation and swelling. Antihistamines combat these effects by competing with histamine for these receptor sites. By...
01:16The Respiratory System
01:19Respiratory Assessment: Purpose and Indications
Objectives and Importance:
The primary goal of respiratory assessment is to evaluate patients at early risk of clinical deterioration. Since respiratory distress often precedes other signs of declining health, breathing patterns and sounds become a...